Boston Life Sciences Announces Organizational Changes; Dr. Mark Pykett

    Business Editors/Health/Medical Writers

    BOSTON--(BUSINESS WIRE)--Feb. 3, 2005--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced that Dr. Mark Pykett will become President and Chief Operating Officer of the Company, effective February 4, 2005.
    "My fellow directors and I are pleased to announce Mark's appointment" stated Peter Savas, the Company's Chairman. "He will lead the clinical development of ALTROPANE(R) in diagnosing Parkinson's disease and ADHD, as well as the pre-clinical development of Inosine and O-1369 in treating stroke and Parkinson's disease, respectively. Mark will also direct the rationalization of our intellectual property estate and new product pipeline."
    "Our programs have the potential to address important medical needs," noted Dr. Pykett. "I am especially pleased to manage the development of ALTROPANE(R). If we are successful, ALTROPANE(R)will improve the medical community's ability to differentiate Parkinson's disease from non-Parkinsonian movement disorders. ALTROPANE(R)may also be a useful analytical tool for objectively diagnosing ADHD. Our lead pre-clinical drug candidates target two debilitating medical conditions: Parkinson's disease and stroke. I look forward to working with the talented people at Harvard and Children's Hospital to advance both programs toward the clinic."

    Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of novel diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R), the company's lead program, is in Phase III for the diagnosis of Parkinson's disease and Phase II for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include O-1369 for the treatment of Parkinson's disease and Inosine for the treatment of stroke. BLSI's current research collaborations include Harvard Medical School, Children's Hospital of Boston and the University of Massachusetts-Worcester.

    Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, achievements and milestones, schedules of IND, NDA and all other regulatory submissions and the possible approval of products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, delays in the regulatory or development processes, results from clinical and pre-clinical trials, regulatory decisions, market acceptance of the Company's products, the ability to obtain intellectual property protection, the outcome of discussions with potential partners and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.

--30--SP/bo*

CONTACT: Boston Life Sciences, Inc. Joseph Hernon, 617-425-0200 Chief Financial Officer jhernon@bostonlifesciences.com

KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Boston Life Sciences, Inc.

Copyright Business Wire 2005